---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic burden and healthcare resource utilization. Topics: Incremental all-cause healthcare costs: United States Medicare Advantage claims, Healthcare resource utilization rate ratios: United States Medicare Advantage claims, Geographic atrophy-specific outpatient visits and costs by severity: United States commercial claims, Total cost of care by visual acuity impairment: IRIS Registry linked to claims, and 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Incremental all-cause healthcare costs: United States Medicare Advantage claims

> “Patients with GA only incurred higher annual all-cause total healthcare costs compared to patients with no GA ($26,696 vs $25,524), spending an average of $1,171 (95% CI: 204, 2,138) more per year (P=0.018). The difference in all-cause total healthcare costs was primarily driven by higher annual OP visit costs ($10,706 vs $9,996; adjusted cost difference: $740; 95% CI: 194, 1,286; P=0.008).”
> “Compared to patients with GA only, patients with GA + VI incurred higher all-cause total healthcare costs ($35,654 vs $30,558), spending an average of $5,096 (95% CI: 2,811, 7,381) more per year (P<0.001).”
> “With the additional burden of blindness, patients with GA + B spent an average of $9,952 (95% CI: 6,172, 13,733) more per year in all-cause total healthcare costs compared to patients with GA only (P<0.001).”
> “Costs were inflation-adjusted to 2021 US dollars using the medical care component of the Consumer Price Index.”

Source: [Sarda et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559221/)

<a id="topic-2.2.1.8.2-2"></a>

### Healthcare resource utilization rate ratios: United States Medicare Advantage claims

> “The study included 18,119 patients with GA only, 2,285 with GA + VI, 1,716 with GA + B, and 72,476 patients without GA. Higher rates of all-cause hospitalizations (RR [95% CI]: 1.08 [1.03, 1.12]), outpatient visits (1.08 [1.05, 1.10]), other visits (1.14 [1.08, 1.21]), and falls with head injuries (1.24 [1.05, 1.45]) were observed in patients with GA vs without GA (P<0.05).”
> “Patients with GA + B had higher rates of all-cause and ophthalmic condition-related hospitalizations, ER visits, and other visits PPY than patients with GA only (all P<0.05), with 2.88 (95% CI: 2.14, 3.86) times more ophthalmic condition-related hospitalizations, 1.74 (95% CI: 1.14, 2.66) times more ophthalmic condition-related ER visits, and 2.41 (95% CI: 1.90, 3.05) times more ophthalmic condition-related other visits.”

Source: [Sarda et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559221/)

> “Compared to controls, patients with GA also had an increased risk for hospitalization (RR 1.18–1.27), emergency department visits (RR 1.18–1.21), nursing home or assisted living admissions (RR 1.06–1.28), and outpatient visits (RR 1.05–1.08).”
> “The Clinformatics®, MarketScan, and PharMetrics datasets included 44,591, 9470, and 27,428 patients with GA, respectively.”

Source: [Hu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006262/)

> “There was no statistically significant difference between the 2 cohorts in the use of health care resources like inpatient stays, length of stay, ED visits, and telehealth services, except for higher number of outpatient visits in individuals with GA (mean [SD] = 18.3 [15.9] vs 16.7 [15.9]; GA vs non-GA cohort, respectively, P < 0.001)”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.8.2-3"></a>

### Geographic atrophy-specific outpatient visits and costs by severity: United States commercial claims

> “A total of 28,773 GA cases were identified (mean age = 68.7; 58.5% female), of which 24% and 76% had unilateral and bilateral GA, respectively”
> “Patients with greater baseline severity in the bilateral group had a significantly higher number of outpatient (OP) visits per year (1.98 EI AMD; 2.57 for GAwoSF; 2.63 for GAwSF).”
> “Similarly, higher payer-related costs were seen in patients with bilateral GAwSF compared to bilateral EI AMD (mean [SD] $280 [$325]; $198 [$262]).”
> “Overall, however, the actual costs were not large, ranging from $56–$110, given that these were disease-specific, and not all-cause, costs and thus, we would be capturing outpatient visits that do not require any active therapy.”

Source: [Kim et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8236262/)

<a id="topic-2.2.1.8.2-4"></a>

### Total cost of care by visual acuity impairment: IRIS Registry linked to claims

> “A total of 5827 patients were included in the closed-claims cohorts. By year 2, VA impairment was associated with an increase of more than 26% in total cost of care.”
> “In models through year 2, mild (20/25 to 20/40) and moderate (20/50 to 20/100) VA impairment were associated with a more than 30% increase in total cost of care; moderately severe VA impairment (20/125 to 20/200) was associated with a 26% increase in cost; and severe VA impairment (worse than 20/200) was associated with a 43% increase in cost (mild: adjusted cost ratio, 1.31 [95% CI, 0.98-1.74, P = .061); moderate: adjusted cost ratio, 1.37 [95% CI, 1.00-1.86], P = .045; moderately severe: adjusted cost ratio, 1.26 [95% CI, 0.86-1.83], P = .237; severe: adjusted cost ratio, 1.43 [95% CI, 0.88-2.34], P = .127).”

Source: [Borkar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13226300/)

<a id="topic-2.2.1.8.2-5"></a>

### First-year all-cause costs and indirect costs: systematic literature review

> “In a US retrospective study (N = 14,421), mean total first-year cost postdiagnosis per patient with GA to the health-care system was US $11,672 (Figure 1).34”
> “Costs presented in the included studies were converted, as applicable, to US dollars (USD) in the reported cost year; all costs were then inflated to 2020 USD.”
> “Our review identified only 7 studies with heterogeneous methodologies reporting on resource utilization and costs associated with GA, and no economic models. We identified only one study, published in 2005, on indirect costs.”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.2-6"></a>

### Societal cost of illness per person with geographic atrophy: United States estimate

| Cost category, United States, per person per year | Geographic atrophy, € (% of total) | Neovascular AMD, € (% of total) |
| --- | --- | --- |
| Direct medical cost | “327 (0.8)” | “9073 (18.5)” |
| Indirect medical cost | “12 744 (32.5)” | “3385 (7.0)” |
| Well-being cost | “11 948 (30.4)” | “13 702 (28.0)” |
| Productivity cost | “14 232 (36.3)” | “22 714 (46.5)” |
| Total | “39 251 (100)” | “48 874 (100)” |
| Financial costs | “27 303 (69.6)” | “35 172 (72)” |

Source: [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/)

> “Estimated per-annum total costs attributable to late-stage AMD were €449.5 million ($512.5 million) in Bulgaria, €7.6 billion ($8.6 billion) in Germany, and €43.2 billion ($49.4 billion) in the US.”
> “The financial costs incurred due to nAMD amounted to €17.2 billion ($19.7 billion) and totaled €13.4 billion ($15.3 billion) for GA (Table 3).”
> “We observed higher direct medical costs for nAMD compared with GA across all countries. This finding is reasonable given the fact that several treatment options were available for nAMD but not for GA at the time of conducting this research.”
> “First, the patient survey data were based on a relatively small sample of participants in each country; therefore, the model may have over- or underestimated certain cost parameters.”

Source: [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/)

<a id="topic-2.2.1.8.2-7"></a>

### Direct and indirect ophthalmic resource use and costs: United Kingdom, Germany, Ireland, and Canada

> “In the 24 months before study inclusion, 85.4% of patients with GA had an ophthalmology-related visit, 81.5% had at least one test or procedure (averaging 8.2–9.6 tests/procedures per year), and 10% accessed home health care services.”
> “The associated mean annual costs for direct ophthalmological resource per patient amounted to €1772, comprising €188 for ophthalmology-related visits, €1071 for tests/procedures, €116 for drugs or other treatments, €319 for home health care services, €63 for vision-related equipment, and €14 for eye rehabilitation services (Table S6).”
> “The associated mean annual costs for indirect ophthalmological resource use per patient were €234, comprising €177 for GP visits, €12 for emergency department visits, €39 for inpatient admissions, and €7 for outpatient admissions (Table S6).”
> “The annualized average total cost (direct and indirect ophthalmic HCRU) was €2006 per patient with GA, with direct health care costs accounting for most of these costs.”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

<a id="topic-2.2.1.8.2-8"></a>

### Costs of vision loss and blindness in the United States: all causes

> “We estimated an economic burden of VL of $134.2 billion: $98.7 billion in direct costs and $35.5 billion in indirect costs. The largest burden components were NH ($41.8 billion), other medical care services ($30.9 billion), and reduced labor force participation ($16.2 billion), all of which accounted for 66% of the total. Those with VL incurred $16 838 per year in incremental burden.”
> “Informal care was the largest burden component for people 0 to 18 years of age, reduced labor force participation was the largest burden component for people 19 to 64 years of age, and NH costs were the largest burden component for people 65 years of age or older.”

Source: [Rein et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34560128/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
